AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
Healthcare
$5.22 +0.82%
+$0.04 today
- Market cap
- $198.07M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
52W Low $1.00High $6.91
Volume 0.79M
Average 0.29M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$29.83M
FY 2025 · Annual
Investing Cash Flow
$28.31M
FY 2025 · Annual
-48.1% YoYFinancing Cash Flow
$113,000.00
FY 2025 · Annual
-69.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.54M) | (40.96M) | (64.73M) | (51.32M) | (35.17M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 974K | 4.39M | 8.41M | 8.34M | 6.25M |
| Change in Working Capital | 32K | 3.72M | 5.83M | (3M) | 164K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 417K | 2.5M | 553K | 641K | (296K) |
| Other Working Capital | (385K) | 1.22M | 5.28M | (3.64M) | 460K |
| Other Non-Cash Items | 53K | (615K) | (2.8M) | (3.28M) | (1.07M) |
| Operating Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (77.27M) | (93.84M) | (132.18M) | (46.75M) | (46.19M) |
| Sales of Investments | 27.25M | 72.07M | 88.9M | 101.34M | 74.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.02M) | (21.77M) | (43.28M) | 54.59M | 28.31M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 70.37M | 84.53M | 372K | 113K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.2M) | (11K) | 465K | 0 | 0 |
| Financing Cash Flow | 78.54M | 70.36M | 84.99M | 372K | 113K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.03M | 15.12M | (11.57M) | 5.7M | (1.41M) |
| Free Cash Flow | (20.48M) | (33.46M) | (53.29M) | (49.26M) | (29.83M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$35.2M
+ D&A$0
+ Stock-Based Comp$6.2M
+ Deferred Tax$0
+ Working Capital$164.0K
- Other Non-Cash-$1.1M
= Operating Cash Flow-$29.8M
- Capex$0
= Free Cash Flow-$29.8M
Analysis
FY2025 free cash flow is -$29.8M. FCF conversion is 84.8% of net income. Operating cash flow was -$29.8M, with capex of $0. The largest bridge item is Stock-Based Comp at $6.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 |
Does ANTX generate free cash flow?
AN2 Therapeutics, Inc. (ANTX) generated -$29.83M of free cash flow in fiscal 2025.
How much operating cash flow does ANTX produce?
Operating cash flow was -$29.83M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.